The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder with no treatments halting its progression, except smoking cessation.
• Oxidative stress is a key factor in COPD pathogenesis.
• N-acetylcysteine (NAC) is an antioxidant agent with potential therapeutic benefits.

Purpose of the Study:

• To assess the effectiveness of N-acetylcysteine (NAC) in slowing the decline of forced expiratory volume in one second (FEV1) in COPD patients.
• To evaluate the impact of NAC on COPD exacerbation rates and patient quality of life.
• To estimate the cost-utility of NAC treatment for moderate to severe COPD.

Main Methods:

• A phase III, randomized, double-blind, placebo-controlled, multicentre trial (BRONCUS) involving 523 patients with moderate to severe COPD.
• Patients were followed for 3 years, with evaluations every 3 months.
• The study assessed changes in FEV1, exacerbation frequency, and quality of life, comparing NAC to placebo.

Main Results:

• The study did not find a significant effect of N-acetylcysteine (NAC) on the rate of decline in FEV1.
• NAC treatment did not significantly reduce the exacerbation rate in patients with moderate to severe COPD.
• No significant differences were observed in quality of life measures between the NAC and placebo groups.

Conclusions:

• N-acetylcysteine (NAC) does not appear to be effective in altering the progression of lung function decline or reducing exacerbations in patients with moderate to severe COPD.
• The findings suggest that NAC is not a beneficial treatment for improving outcomes in this patient population.
• Further research may be needed to explore other therapeutic targets for COPD management.